Cabotegravir was found to be 69% more effective in preventing HIV acquisition in men who have sex with men (MSM) and transgender women who have sex with men when compared to the current standard of care
(PRWeb May 18, 2020)
Read the full story at https://www.prweb.com/releases/global_hiv_prevention_study_ends_early_after_injectable_cabotegravir_shows_high_efficacy/prweb17130708.htm
For more information, please visit
https://www.prweb.com/releases/global_hi[...]igh_efficacy/prweb17130708.htm